​

        Genomic and transcriptional profiling stratifies VQ myeloma lines into two clusters with distinct risk signatures and                                                                       drug responses

                                      Preprint in: bioRxiv 2022.08.21.504657; doi.org/10.1101/2022.08.21.504657

                   Flietner E, Yu M, Rajagopalan A, Zhou Y, Feng Y, Veltri A, Lasho T, Wen Z, Sun Y, Burns R, Patnaik MM,                                                                                                Callander NS, Asimakopoulos F, Wang D, Zhang J.

 

Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment.

                                                                                         Cell Reports, 10.1016/j.celrep.2022.111201.

       Papadas A, Deb G, Cicala A, Officer A, Hope C, Pagenkopf A, Flietner E, Morrow Z, Emmerich P, Wiesner J, Arauz G, Bansal V, Esbona                         K, Matkowskyj KA, Capitini C, Deming D, Politi K, Abrams SI, Harismendy O, and Asimakopoulos F.

​

Matrix proteoglycans in tumor inflammation and immunity

                                    American Journal of Physiology- Cell Physiology, 2022 Jul 25. doi: 10.1152/ajpcell.00023.2022.                                           Deb G, Cicala A, Papadas A, and Asimakopoulos F.

​

Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model

                                                      Sci Reports, 2022 Jun 23;12(1):10616. doi: 10.1038/s41598-022-14114-z.

Flietner E, Wen Z, Rajagopalan A, Jung O, Wiesner J, You X, Zou Y, Bakke B, Callander N, Rapraeger A G, Marulasiddappa S, Asimakopoulos F and Zhang, J.

​

Proceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma

                        Journal Transplantation and Cellular Therapy, 2022 May 21:S2666-6367(22)01312-4. doi: 10.1016/j.jtct.2022.05.019.                                       Holstein SA, Asimakopoulos F, Abdel Kareem A, Bianchi G, Bhutani M, Crews L, Cupedo T, Giles H, Gooding S, Hillengass J,                              John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani                            SZ, and McCarthy PL.

​

Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.

Blood. 2021 Jan 7;137(1):61-74. doi: 10.1182/blood.2020007156.

Wen Z, Rajagopalan A, Flietner E, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen JL, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F,  Zhang J

 

Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.

Journal of Histochemistry & Cytochemistry, 2020

Papadas A, Arauz G, Cicala A, Weisner J, Asimakopoulos F.

​

​

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.

Leuk Lymphoma. 2019 10; 60(10):2558-2562.

Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F.

​

TIGIT checkpoint inhibition for myeloma.

Blood. 2018 10 18; 132(16):1629-1630.

Asimakopoulos F.

​

Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.

J Immunother Cancer. 2018 07 03; 6(1):65.

Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F.

​

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

JAMA Oncol. 2018 Mar 01; 4(3):343-350.

Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN.

​

Mechanisms of Resistance in Multiple Myeloma.

Handb Exp Pharmacol. 2018; 249:251-288.

Papadas A, Asimakopoulos F.

​

Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma.

J Biol Chem. 2018 02 16; 293(7):2452-2465.

Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S.

​

Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

J Leukoc Biol. 2017 08; 102(2):265-275.

Asimakopoulos F, Hope C, Johnson MG, Pagenkopf A, Gromek K, Nagel B.  

 

Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.

Blood. 2016 08 04; 128(5):680-5.

Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F.  

 

Deploying myeloid cells against myeloma.

Oncoimmunology. 2016 Mar; 5(3):e1090076.

Jensen JL, Hope C, Asimakopoulos F.  

 

Single-molecule analysis reveals widespread structural variation in multiple myeloma.

Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7689-94.

Gupta A, Place M, Goldstein S, Sarkar D, Zhou S, Potamousis K, Kim J, Flanagan C, Li Y, Newton MA, Callander NS, Hematti P, Bresnick EH, Ma J, Asimakopoulos F, Schwartz DC. 

 

MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

Integr Biol (Camb). 2015 Jun; 7(6):643-54.

Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. 

 

Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Cancer Immunol Res. 2015 Aug; 3(8):881-90.

Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F.  

 

Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network.

Cancer Chemother Pharmacol. 2014 Oct; 74(4):875-82.

Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S.  

 

TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Blood. 2014 May 22; 123(21):3305-15.

Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F.  

​

Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Leuk Lymphoma. 2013 Oct; 54(10):2112-21.

Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P.  

 

MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages.

Br J Haematol. 2013 Mar; 160(6):779-84.

Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, Maroulakou I, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F.  

​